At Johnson & Johnson, we are committed to fighting haematological malignancies by addressing unmet needs and staying at the forefront of innovation. Learn more about our innovative therapies for Multiple Myeloma, Chronic Lymphocytic Leukemia, and other haematological malignancies.

At Johnson & Johnson, we believe that more ambitious targets in IBD are within reach. Learn more about how we support ambitious treatment objectives in Crohn’s disease and ulcerative colitis.

Johnson & Johnson stands by healthcare professionals in the care of patients with Psoriasis. Discover useful information for every stage of patient care, closely aligned with your clinical practice.

Recognizing depression as one of the leading causes of disability worldwide, Janssen is developing a new therapeutic approach for treatment-resistant depression (TRD). Expert interviews, patient profiles, and practical recommendations are available to support the management of patients with TRD or those experiencing a psychiatric emergency (MDDPE).

Prostate cancer and lung cancer are the main areas of focus for Johnson & Johnson Oncology. Discover Johnson & Johnson innovative therapeutic options in Oncology. Stay informed about the latest data and patient monitoring strategies based on the stage of the disease.

At Janssen, we are spearheading a new era for PH, working to transform the disease into a long-term manageable condition, so that patients can live a normal life.